Cargando…

Interest of Supportive and Barrier Protective Skin Care Products in the Daily Prevention and Treatment of Cutaneous Toxicity During Radiotherapy for Breast Cancer

PURPOSE: As many as 50% of patients with cancer develop acute skin reactions to some degree with radiotherapy. Proactive skin care is often recommended to minimise these skin reactions and maintain the integrity of the epidermal barrier; nevertheless, no consensual guidelines are systematically used...

Descripción completa

Detalles Bibliográficos
Autores principales: Berger, Antoine, Regueiro, Carlos, Hijal, Tarek, Pasquier, David, De La Fuente, Cristina, Le Tinier, Florence, Coche-Dequeant, Bernard, Lartigau, Eric, Moyal, Dominique, Seité, Sophie, Bensadoun, René-Jean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802618/
https://www.ncbi.nlm.nih.gov/pubmed/29434476
http://dx.doi.org/10.1177/1178223417752772
_version_ 1783298556000468992
author Berger, Antoine
Regueiro, Carlos
Hijal, Tarek
Pasquier, David
De La Fuente, Cristina
Le Tinier, Florence
Coche-Dequeant, Bernard
Lartigau, Eric
Moyal, Dominique
Seité, Sophie
Bensadoun, René-Jean
author_facet Berger, Antoine
Regueiro, Carlos
Hijal, Tarek
Pasquier, David
De La Fuente, Cristina
Le Tinier, Florence
Coche-Dequeant, Bernard
Lartigau, Eric
Moyal, Dominique
Seité, Sophie
Bensadoun, René-Jean
author_sort Berger, Antoine
collection PubMed
description PURPOSE: As many as 50% of patients with cancer develop acute skin reactions to some degree with radiotherapy. Proactive skin care is often recommended to minimise these skin reactions and maintain the integrity of the epidermal barrier; nevertheless, no consensual guidelines are systematically used. This multicentre, observational, prospective study evaluated the tolerability and benefit of supportive and barrier protective skin care products in preventing radiotherapy-induced skin reactions in 253 women initiating radiotherapy (exclusive or adjuvant) for breast cancer. METHODS: Patients received a kit of 5 commercially available skin care products before the first radiotherapy treatment. The following variables were assessed: cutaneous adverse events, investigator-assessed skin reactions (oedema, erythema, dryness, desquamation) before and after radiotherapy course, investigator, and patient opinion on products benefit. Results were analysed by frequency of product use (heavy versus low). RESULTS: Average age was 60 years (range: 34-85). Over 92% of patients reported good to excellent tolerance on irradiated skin for each product. During the 6-week radiotherapy period, we observed that heavy product users had less skin reactions than the low users, particularly within 10 days of radiotherapy initiation (8% versus 18%; p = .031). Positive physician’s opinion on product use was more frequent for high (66.6%) versus low (32%) users. Patient-assessed patient benefit index was generally >1, indicating relevant treatment benefit, with a tendency for better benefit in high versus low users. CONCLUSIONS: These results support recommendations to use skin care products to minimise the impact of secondary cutaneous reactions with radiotherapy cancer treatment.
format Online
Article
Text
id pubmed-5802618
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-58026182018-02-12 Interest of Supportive and Barrier Protective Skin Care Products in the Daily Prevention and Treatment of Cutaneous Toxicity During Radiotherapy for Breast Cancer Berger, Antoine Regueiro, Carlos Hijal, Tarek Pasquier, David De La Fuente, Cristina Le Tinier, Florence Coche-Dequeant, Bernard Lartigau, Eric Moyal, Dominique Seité, Sophie Bensadoun, René-Jean Breast Cancer (Auckl) Original Research PURPOSE: As many as 50% of patients with cancer develop acute skin reactions to some degree with radiotherapy. Proactive skin care is often recommended to minimise these skin reactions and maintain the integrity of the epidermal barrier; nevertheless, no consensual guidelines are systematically used. This multicentre, observational, prospective study evaluated the tolerability and benefit of supportive and barrier protective skin care products in preventing radiotherapy-induced skin reactions in 253 women initiating radiotherapy (exclusive or adjuvant) for breast cancer. METHODS: Patients received a kit of 5 commercially available skin care products before the first radiotherapy treatment. The following variables were assessed: cutaneous adverse events, investigator-assessed skin reactions (oedema, erythema, dryness, desquamation) before and after radiotherapy course, investigator, and patient opinion on products benefit. Results were analysed by frequency of product use (heavy versus low). RESULTS: Average age was 60 years (range: 34-85). Over 92% of patients reported good to excellent tolerance on irradiated skin for each product. During the 6-week radiotherapy period, we observed that heavy product users had less skin reactions than the low users, particularly within 10 days of radiotherapy initiation (8% versus 18%; p = .031). Positive physician’s opinion on product use was more frequent for high (66.6%) versus low (32%) users. Patient-assessed patient benefit index was generally >1, indicating relevant treatment benefit, with a tendency for better benefit in high versus low users. CONCLUSIONS: These results support recommendations to use skin care products to minimise the impact of secondary cutaneous reactions with radiotherapy cancer treatment. SAGE Publications 2018-01-23 /pmc/articles/PMC5802618/ /pubmed/29434476 http://dx.doi.org/10.1177/1178223417752772 Text en © The Author(s) 2018 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Berger, Antoine
Regueiro, Carlos
Hijal, Tarek
Pasquier, David
De La Fuente, Cristina
Le Tinier, Florence
Coche-Dequeant, Bernard
Lartigau, Eric
Moyal, Dominique
Seité, Sophie
Bensadoun, René-Jean
Interest of Supportive and Barrier Protective Skin Care Products in the Daily Prevention and Treatment of Cutaneous Toxicity During Radiotherapy for Breast Cancer
title Interest of Supportive and Barrier Protective Skin Care Products in the Daily Prevention and Treatment of Cutaneous Toxicity During Radiotherapy for Breast Cancer
title_full Interest of Supportive and Barrier Protective Skin Care Products in the Daily Prevention and Treatment of Cutaneous Toxicity During Radiotherapy for Breast Cancer
title_fullStr Interest of Supportive and Barrier Protective Skin Care Products in the Daily Prevention and Treatment of Cutaneous Toxicity During Radiotherapy for Breast Cancer
title_full_unstemmed Interest of Supportive and Barrier Protective Skin Care Products in the Daily Prevention and Treatment of Cutaneous Toxicity During Radiotherapy for Breast Cancer
title_short Interest of Supportive and Barrier Protective Skin Care Products in the Daily Prevention and Treatment of Cutaneous Toxicity During Radiotherapy for Breast Cancer
title_sort interest of supportive and barrier protective skin care products in the daily prevention and treatment of cutaneous toxicity during radiotherapy for breast cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802618/
https://www.ncbi.nlm.nih.gov/pubmed/29434476
http://dx.doi.org/10.1177/1178223417752772
work_keys_str_mv AT bergerantoine interestofsupportiveandbarrierprotectiveskincareproductsinthedailypreventionandtreatmentofcutaneoustoxicityduringradiotherapyforbreastcancer
AT regueirocarlos interestofsupportiveandbarrierprotectiveskincareproductsinthedailypreventionandtreatmentofcutaneoustoxicityduringradiotherapyforbreastcancer
AT hijaltarek interestofsupportiveandbarrierprotectiveskincareproductsinthedailypreventionandtreatmentofcutaneoustoxicityduringradiotherapyforbreastcancer
AT pasquierdavid interestofsupportiveandbarrierprotectiveskincareproductsinthedailypreventionandtreatmentofcutaneoustoxicityduringradiotherapyforbreastcancer
AT delafuentecristina interestofsupportiveandbarrierprotectiveskincareproductsinthedailypreventionandtreatmentofcutaneoustoxicityduringradiotherapyforbreastcancer
AT letinierflorence interestofsupportiveandbarrierprotectiveskincareproductsinthedailypreventionandtreatmentofcutaneoustoxicityduringradiotherapyforbreastcancer
AT cochedequeantbernard interestofsupportiveandbarrierprotectiveskincareproductsinthedailypreventionandtreatmentofcutaneoustoxicityduringradiotherapyforbreastcancer
AT lartigaueric interestofsupportiveandbarrierprotectiveskincareproductsinthedailypreventionandtreatmentofcutaneoustoxicityduringradiotherapyforbreastcancer
AT moyaldominique interestofsupportiveandbarrierprotectiveskincareproductsinthedailypreventionandtreatmentofcutaneoustoxicityduringradiotherapyforbreastcancer
AT seitesophie interestofsupportiveandbarrierprotectiveskincareproductsinthedailypreventionandtreatmentofcutaneoustoxicityduringradiotherapyforbreastcancer
AT bensadounrenejean interestofsupportiveandbarrierprotectiveskincareproductsinthedailypreventionandtreatmentofcutaneoustoxicityduringradiotherapyforbreastcancer